AR015500A1 - 11 BETA-HALOGEN-STRATRIENS REPLACED IN 7 ALPHA, PROCEDURE FOR PREPARING PHARMACEUTICAL PREPARATIONS THAT CONTAIN SUCH 11 BETA-HALOGEN-STRATRIENS REPLACED IN 7 ALPHA, AS WELL AS USED IN THE PREPARATION OF MEDICINES. - Google Patents
11 BETA-HALOGEN-STRATRIENS REPLACED IN 7 ALPHA, PROCEDURE FOR PREPARING PHARMACEUTICAL PREPARATIONS THAT CONTAIN SUCH 11 BETA-HALOGEN-STRATRIENS REPLACED IN 7 ALPHA, AS WELL AS USED IN THE PREPARATION OF MEDICINES.Info
- Publication number
- AR015500A1 AR015500A1 ARP980106471A ARP980106471A AR015500A1 AR 015500 A1 AR015500 A1 AR 015500A1 AR P980106471 A ARP980106471 A AR P980106471A AR P980106471 A ARP980106471 A AR P980106471A AR 015500 A1 AR015500 A1 AR 015500A1
- Authority
- AR
- Argentina
- Prior art keywords
- carbon atoms
- alkenyl
- branched
- beta
- alpha
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0072—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the A ring of the steroid being aromatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
Abstract
11 beta-halogeno-estratrienos sustituidos en 7 alfa, de formula I en donde R3 representa un átomo de hidrogeno, un resto de hidrocarburo con hasta 8 átomosde carbono o un resto de la subformula R3 - C(O)-, donde R3 representa un átomo de hidrogeno oun resto de hidrocarburo con hasta 8 átomos de carbono o unresto fenilo, R7 representa un resto con la formula -A-B-Z-R20, donde A figura un enlace directo o un resto bencilideno, donde el grupo metileno está enlazadoal átomo de carbono 7 delesteroi de, o un resto fenilo, Bfigura para un grupo alquileno, alquenilo o alquinilo con 3 a 14 átomos de carbono, lineal oramificado; y Z figura para un grupo -NR21, y R21 para un grupo alquilo C1-3, donde , entonces R20 representa un átomo dehidrogeno, u n grupo alquilo,alquenilo o alquinilo con hasta 10 átomos de carbono, lineal o ramificado, o uno de los agrupamientos D-CnF2n + 1, donde D representa un grupo alquileno,alquenilo o alquinilo con hasta 8 átomos de carbono, lineal oramificado, y n un numero entero de 1 a 8, L-CH = CF - CpF2p + 1, donde L representa un grupoalquileno, alquenilo o alquinilo con C2-7, lineal o ramificado, y representa un numero entero de 2 a 7, D-O-(CH2)-q-arilo, donde D representa lo mismo queloya indicado, q a 0, 1, 2 o 3 y arilo figura para un resto fenilo o 1- o 2-naftilo, en casos dados, sustituido una o dos veces, o un resto heteroarilo,D-O-(CH2)r-CnF2n + 1, donde D y n representan lo mismo que lo ya indicado, y r figura para unnumero entero de 1 a 5, o R20 y R21, junto con el nitrogeno alque están unidos, forman un heterociclo saturado o insaturado con 5 o 6 miembros de cadena que, en casos dados, contiene uno o dos heteroátomos seleccionadosentre nitrogeno, oxígeno yazufre y en casos dados, es ta sustituido o Z figura para -SOx- y x para 0, 1 o 2, donde, entonces, R20 representa un grupo alquilo,alquenilo o alquinilo con hasta 10 átomos de carbono, lineal o ramificado, o uno de los agrupamientos D-CnF2n + 1,donde D representa un grupo alq uileno,alquenilo o alquinilo con hasta 8 átomos de carbono, lineal o ramificado, y n un numero entero de 1 a 8, L - CH = CF - CpF2p + 1, donde L representa un11 beta-halogen-estratriennes substituted in 7 alpha, of formula I wherein R3 represents a hydrogen atom, a hydrocarbon residue with up to 8 carbon atoms or a remainder of the subformula R3-C (O) -, where R3 represents a hydrogen atom or a hydrocarbon residue with up to 8 carbon atoms or a phenyl residue, R7 represents a residue with the formula -ABZ-R20, where A contains a direct bond or a benzylidene residue, where the methylene group is linked to the carbon atom 7 delesteroi of, or a phenyl moiety, Bfigura for an alkylene, alkenyl or alkynyl group with 3 to 14 carbon atoms, linearly branched; and Z is for a group -NR21, and R21 for a C1-3 alkyl group, where, then R20 represents a hydrogen atom, an alkyl, alkenyl or alkynyl group with up to 10 carbon atoms, linear or branched, or one of the D-CnF2n + 1 groupings, where D represents an alkylene, alkenyl or alkynyl group with up to 8 carbon atoms, linearly branched, and n an integer from 1 to 8, L-CH = CF - CpF2p + 1, where L represents a C2-7 alkylene, alkenyl or alkynyl group, linear or branched, and represents an integer from 2 to 7, DO- (CH2) -q-aryl, where D represents the same as indicated, qa 0, 1, 2 or 3 and aryl appears for a phenyl or 1- or 2-naphthyl moiety, in given cases, substituted once or twice, or a heteroaryl moiety, DO- (CH2) r-CnF2n + 1, where D and n represent the same as already indicated, and figure for a whole number of 1 to 5, or R20 and R21, together with the nitrogen to which they are attached, form a saturated or unsaturated heterocycle with 5 or 6 chain members which, in given cases, contains one or two heteroatoms selected from nitrogen, oxygen and sulfur and in given cases, it is substituted or Z is shown for -SOx- and x for 0, 1 or 2, where, then, R20 represents an alkyl, alkenyl group or alkynyl with up to 10 carbon atoms, linear or branched, or one of the D-CnF2n + 1 groupings, where D represents an alkyl, alkenyl or alkynyl group with up to 8 carbon atoms, linear or branched, and an integer from 1 to 8, L - CH = CF - CpF2p + 1, where L represents a
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE1997158390 DE19758390A1 (en) | 1997-12-23 | 1997-12-23 | New 11beta-halo-7alpha-substituted-estratriene derivatives are useful for treatment e.g. various cancers, anovulatolial infertility, male hair loss, osteoporosis, and contraceptives |
| DE1998106357 DE19806357A1 (en) | 1998-02-10 | 1998-02-10 | New 11 beta-halo-7 alpha-substituted estratrienes useful for treating e.g. estrogen-dependent disease such as breast cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR015500A1 true AR015500A1 (en) | 2001-05-02 |
Family
ID=26042916
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP980106471A AR015500A1 (en) | 1997-12-23 | 1998-12-18 | 11 BETA-HALOGEN-STRATRIENS REPLACED IN 7 ALPHA, PROCEDURE FOR PREPARING PHARMACEUTICAL PREPARATIONS THAT CONTAIN SUCH 11 BETA-HALOGEN-STRATRIENS REPLACED IN 7 ALPHA, AS WELL AS USED IN THE PREPARATION OF MEDICINES. |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US6780855B2 (en) |
| EP (1) | EP1042355B1 (en) |
| JP (1) | JP2001527088A (en) |
| KR (1) | KR20010024806A (en) |
| CN (1) | CN1131235C (en) |
| AR (1) | AR015500A1 (en) |
| AT (1) | ATE232543T1 (en) |
| AU (1) | AU750801B2 (en) |
| BG (1) | BG104553A (en) |
| BR (1) | BR9814416A (en) |
| CA (1) | CA2316444A1 (en) |
| DE (1) | DE59807213D1 (en) |
| DK (1) | DK1042355T3 (en) |
| EA (1) | EA002623B1 (en) |
| EE (1) | EE200000380A (en) |
| ES (1) | ES2191371T3 (en) |
| HU (1) | HUP0100568A3 (en) |
| ID (1) | ID26207A (en) |
| IL (1) | IL136938A0 (en) |
| IS (1) | IS5526A (en) |
| NO (1) | NO20003286L (en) |
| NZ (1) | NZ505348A (en) |
| PE (1) | PE20000129A1 (en) |
| PL (1) | PL341299A1 (en) |
| SK (1) | SK9442000A3 (en) |
| TR (1) | TR200001973T2 (en) |
| WO (1) | WO1999033855A1 (en) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002032429A2 (en) * | 2000-10-18 | 2002-04-25 | Schering Aktiengesellschaft | Use of inhibitors of progesterone receptor for treating cancer |
| AU2006202187B2 (en) * | 2001-11-27 | 2008-11-06 | Bayer Schering Pharma Aktiengesellschaft | 17alpah-alkyl-17beta-oxy-estratrienes and intermediate products for their production, uses thereof and pharmaceutical preparations |
| DE10159217A1 (en) * | 2001-11-27 | 2003-06-05 | Schering Ag | 17alpha-alkyl-17ß-oxy-estratrienes and intermediates for their preparation, use of 17alpha-alkyl-17ß-oxy-estratriene for the preparation of medicaments and pharmaceutical preparations |
| US20040242551A1 (en) * | 2003-05-28 | 2004-12-02 | Schering Ag | Composition comprising antiprogestins and pure antiestrogens for prophylaxis and treatment of hormone-dependent diseases |
| AU2003267773A1 (en) * | 2003-10-14 | 2005-04-27 | Council Of Scientific And Industrial Research | (3r, 4r)-trans-3,4-diarylchroman derivatives with estrogenic activity |
| KR20070061526A (en) * | 2004-07-27 | 2007-06-13 | 시코르, 인크. | A PROCESS FOR THE PREPARATION OF 7alpha;-ALKYLATED 19-NORSTEROIDS |
| CN103121962B (en) | 2005-11-22 | 2014-11-12 | 住友化学株式会社 | Organic sulfur compounds and use thereof as arthropodicides |
| DE102007023614A1 (en) | 2007-05-21 | 2008-11-27 | Bayer Schering Pharma Aktiengesellschaft | New amide compounds used for treatment of gynecological diseases e.g. endometriosis, for female fertility control and female hormone replacement therapy, has general formula |
| DE102007049630A1 (en) | 2007-10-11 | 2009-10-29 | Bayer Schering Pharma Aktiengesellschaft | New amide compounds used for therapy and/or prophylaxis of gynecological diseases e.g. endometriosis, for female fertility control and female hormone replacement therapy |
| JP2009001551A (en) | 2007-05-18 | 2009-01-08 | Sumitomo Chemical Co Ltd | Organic sulfur compound and its use for controlling harmful arthropod |
| JP5298631B2 (en) | 2007-05-18 | 2013-09-25 | 住友化学株式会社 | Organic sulfur compounds and their use for controlling harmful arthropods |
| TW200904329A (en) | 2007-05-18 | 2009-02-01 | Sumitomo Chemical Co | Organic sulfur compound and its use for controlling harmful arthropod |
| DE102007032800A1 (en) | 2007-07-10 | 2009-01-15 | Bayer Schering Pharma Aktiengesellschaft | Nonsteroidal progesterone receptor modulators |
| EP2033948A1 (en) * | 2007-08-30 | 2009-03-11 | Bayer Schering Pharma Aktiengesellschaft | Process for preparing Estrogen-antagonistic 11beta-Fluoro-17alpha-alkylestra-1,3,5 (10)-triene-3, 17-diols having a 7alpha-(xi-Alkylamino-omega-perfluoroalkyl)alkyl side chain and alpha-Alkyl(amino)-omega-perfluoro(alkyl)alkanes and processes for their preparation |
| EP2826475B1 (en) | 2007-10-16 | 2019-03-20 | Repros Therapeutics Inc. | Trans-clomiphene for treating diabetes in hypogonadal men |
| EP2053055A1 (en) * | 2007-10-24 | 2009-04-29 | Bayer Schering Pharma Aktiengesellschaft | 11.beta.-fluoro-3-acetoxyestra-3,5-diene-17-one and method for its manufacture |
| DE102007058747A1 (en) | 2007-12-05 | 2009-06-10 | Bayer Schering Pharma Aktiengesellschaft | Nonsteroidal progesterone receptor modulators |
| EP2070942A1 (en) | 2007-12-13 | 2009-06-17 | Bayer Schering Pharma Aktiengesellschaft | Method for aromatising 19-nor-androst-4-en-3-ones to estra-1,3,5(10)-trienes |
| EP2070909A1 (en) | 2007-12-15 | 2009-06-17 | Bayer Schering Pharma AG | Non-steroidal progesterone receptor modulators |
| EP2070941A1 (en) | 2007-12-14 | 2009-06-17 | Bayer Schering Pharma Aktiengesellschaft | Stereoselective synthesis of selective estrogen receptor down-regulators |
| EP2258375A1 (en) | 2009-06-04 | 2010-12-08 | Bayer Schering Pharma Aktiengesellschaft | 17B-alkyl-17alpha-oxy-estratrienes |
| DE102009034362A1 (en) | 2009-07-20 | 2011-01-27 | Bayer Schering Pharma Aktiengesellschaft | 17-Hydroxy-17-pentafluoroethyl-estra-4,9 (10) -diene-11-aryl derivatives, process for their preparation and their use for the treatment of diseases |
| DE102009034366A1 (en) | 2009-07-20 | 2011-01-27 | Bayer Schering Pharma Aktiengesellschaft | 17-Hydroxy-17-pentafluoroethyl-estra-4,9 (10) -diene-11-methyleneoxyalkylene aryl derivatives, process for their preparation and their use for the treatment of diseases |
| DE102009034368A1 (en) | 2009-07-20 | 2011-01-27 | Bayer Schering Pharma Aktiengesellschaft | 17-Hydroxy-17-pentafluoroethyl-estra-4,9 (10) -diene-11-acyloxyalkylenephenyl derivatives, process for their preparation and their use for the treatment of diseases |
| DE102009034367A1 (en) | 2009-07-20 | 2011-01-27 | Bayer Schering Pharma Aktiengesellschaft | 17-Hydroxy-17-pentafluoroethyl-estra-4,9 (10) -diene-11-benzylidene derivatives, process for their preparation and their use for the treatment of diseases |
| DE102009034525A1 (en) | 2009-07-21 | 2011-01-27 | Bayer Schering Pharma Aktiengesellschaft | 17-Hydroxy-17-pentafluoroethyl-estra-4,9 (10) -diene-11-aryl derivatives, process for their preparation and their use for the treatment of diseases |
| DE102009034526A1 (en) | 2009-07-21 | 2011-02-10 | Bayer Schering Pharma Aktiengesellschaft | 17-Hydroxy-17-pentafluoroethyl-estra-4,9 (10) -diene-11-ethynylphenyl derivatives, process for their preparation and their use for the treatment of diseases |
| DE102010007719A1 (en) | 2010-02-10 | 2011-08-11 | Bayer Schering Pharma Aktiengesellschaft, 13353 | Progesterone receptor antagonist |
| DE102010007722A1 (en) | 2010-02-10 | 2011-08-11 | Bayer Schering Pharma Aktiengesellschaft, 13353 | Progesterone receptor antagonist |
| DE102010030538A1 (en) | 2010-06-25 | 2011-12-29 | Bayer Schering Pharma Aktiengesellschaft | 6,7-Dihydro-5H-benzo [7] annulene derivatives, process for their preparation, pharmaceutical preparations containing them and their use for the preparation of medicaments |
| DE102011004899A1 (en) | 2011-03-01 | 2012-09-06 | Bayer Pharma Aktiengesellschaft | New 17-hydroxy-17-pentafluoroethyl-estra-4,9(10)-dien-11-aryl-derivatives are progesterone receptor antagonists useful to treat and prevent e.g. uterine fibroids, endometriosis, heavy menstrual bleeding and meningioma |
| DE102011087987A1 (en) | 2011-12-08 | 2013-06-13 | Bayer Intellectual Property Gmbh | 6,7-Dihydro-5H-benzo [7] annulene derivatives, process for their preparation, pharmaceutical preparations containing them and their use for the preparation of medicaments |
| WO2013130832A1 (en) | 2012-02-29 | 2013-09-06 | Repros Therapeutics Inc. | Combination therapy for treating androgen deficiency |
| KR102198059B1 (en) | 2013-04-11 | 2021-01-05 | 바이엘 파마 악티엔게젤샤프트 | Progesterone receptor antagonist dosage form |
| AU2013386732B2 (en) * | 2013-04-18 | 2018-10-18 | Xi'an Libang Pharmaceutical Technology Co., Ltd. | Ester derivative of 7-alpha-[9-(4,4,5,5,5-pentafluoropentylsulphinyl)nonyl]oestra-1,3,5(10)-triene-3,17beta-diol having antitumour activity and preparation method thereof |
| CN104387435B (en) * | 2014-12-10 | 2017-05-10 | 天津孚音生物科技发展有限公司 | Compound and preparation method and application thereof |
| CN106146599A (en) * | 2015-04-07 | 2016-11-23 | 江苏希迪制药有限公司 | A kind of recovery is because of the method for sulfoxide configuration ratio underproof fulvestrant or derivatives thereof |
| EP3373967B9 (en) | 2015-11-10 | 2023-10-04 | Paracrine Therapeutics AB | Treatment of er-negative breast cancer with an pdgf-cc inhibitor and an anti estrogen |
| CN112778089B (en) * | 2021-01-04 | 2023-09-05 | 万知科技股份有限公司 | New synthetic method of 4, 4-trifluoro-1-butanol and homologs thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3076829A (en) * | 1961-09-15 | 1963-02-05 | Schering Corp | Novel 9, 11-disubstituted estratriene derivatives |
| GB8327256D0 (en) * | 1983-10-12 | 1983-11-16 | Ici Plc | Steroid derivatives |
| HU208150B (en) * | 1988-10-31 | 1993-08-30 | Endorecherche Inc | Process for producing new estrogen derivatives having steroid hormone inhibitor activity and pharmaceutical compositions comprising such derivatives |
| US5866560A (en) * | 1996-08-20 | 1999-02-02 | Schering Ag | 7α-(ξ-aminoalkyl)-estratrienes, process for their production, pharmaceutical preparations which contain these 7α-(ξ-aminoalkyl)-estratrienes as well as their use for the production of pharmaceutical agents |
| DE19635525A1 (en) * | 1996-08-20 | 1998-02-26 | Schering Ag | New 7-alpha-(xi-aminoalkyl)- oestratriene derivatives |
-
1998
- 1998-12-18 AR ARP980106471A patent/AR015500A1/en not_active Application Discontinuation
- 1998-12-18 PE PE1998001246A patent/PE20000129A1/en not_active Application Discontinuation
- 1998-12-23 IL IL13693898A patent/IL136938A0/en unknown
- 1998-12-23 CN CN98812631A patent/CN1131235C/en not_active Expired - Fee Related
- 1998-12-23 KR KR1020007006955A patent/KR20010024806A/en not_active Application Discontinuation
- 1998-12-23 AT AT98966410T patent/ATE232543T1/en not_active IP Right Cessation
- 1998-12-23 TR TR2000/01973T patent/TR200001973T2/en unknown
- 1998-12-23 HU HU0100568A patent/HUP0100568A3/en unknown
- 1998-12-23 EP EP98966410A patent/EP1042355B1/en not_active Expired - Lifetime
- 1998-12-23 NZ NZ505348A patent/NZ505348A/en unknown
- 1998-12-23 DE DE59807213T patent/DE59807213D1/en not_active Expired - Fee Related
- 1998-12-23 PL PL98341299A patent/PL341299A1/en unknown
- 1998-12-23 AU AU22763/99A patent/AU750801B2/en not_active Ceased
- 1998-12-23 DK DK98966410T patent/DK1042355T3/en active
- 1998-12-23 EA EA200000711A patent/EA002623B1/en not_active IP Right Cessation
- 1998-12-23 SK SK944-2000A patent/SK9442000A3/en unknown
- 1998-12-23 US US09/380,413 patent/US6780855B2/en not_active Expired - Fee Related
- 1998-12-23 ES ES98966410T patent/ES2191371T3/en not_active Expired - Lifetime
- 1998-12-23 WO PCT/EP1998/008470 patent/WO1999033855A1/en not_active Application Discontinuation
- 1998-12-23 EE EEP200000380A patent/EE200000380A/en unknown
- 1998-12-23 CA CA002316444A patent/CA2316444A1/en not_active Abandoned
- 1998-12-23 BR BR9814416-2A patent/BR9814416A/en not_active IP Right Cessation
- 1998-12-23 ID IDW20001234A patent/ID26207A/en unknown
- 1998-12-23 JP JP2000526531A patent/JP2001527088A/en active Pending
-
2000
- 2000-06-09 IS IS5526A patent/IS5526A/en unknown
- 2000-06-22 NO NO20003286A patent/NO20003286L/en not_active Application Discontinuation
- 2000-06-23 BG BG104553A patent/BG104553A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ATE232543T1 (en) | 2003-02-15 |
| NO20003286D0 (en) | 2000-06-22 |
| CN1131235C (en) | 2003-12-17 |
| DE59807213D1 (en) | 2003-03-20 |
| EA002623B1 (en) | 2002-06-27 |
| NZ505348A (en) | 2002-10-25 |
| HUP0100568A3 (en) | 2002-01-28 |
| CA2316444A1 (en) | 1999-07-08 |
| EP1042355B1 (en) | 2003-02-12 |
| JP2001527088A (en) | 2001-12-25 |
| CN1286693A (en) | 2001-03-07 |
| DK1042355T3 (en) | 2003-04-22 |
| ID26207A (en) | 2000-12-07 |
| EP1042355A1 (en) | 2000-10-11 |
| WO1999033855A1 (en) | 1999-07-08 |
| AU2276399A (en) | 1999-07-19 |
| EE200000380A (en) | 2001-12-17 |
| SK9442000A3 (en) | 2001-04-09 |
| PL341299A1 (en) | 2001-04-09 |
| ES2191371T3 (en) | 2003-09-01 |
| KR20010024806A (en) | 2001-03-26 |
| NO20003286L (en) | 2000-08-23 |
| IL136938A0 (en) | 2001-06-14 |
| EA200000711A1 (en) | 2001-02-26 |
| IS5526A (en) | 2000-06-09 |
| US20030069434A1 (en) | 2003-04-10 |
| BR9814416A (en) | 2000-10-10 |
| BG104553A (en) | 2001-02-28 |
| TR200001973T2 (en) | 2001-01-22 |
| PE20000129A1 (en) | 2000-03-11 |
| AU750801B2 (en) | 2002-07-25 |
| US6780855B2 (en) | 2004-08-24 |
| HUP0100568A2 (en) | 2001-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR015500A1 (en) | 11 BETA-HALOGEN-STRATRIENS REPLACED IN 7 ALPHA, PROCEDURE FOR PREPARING PHARMACEUTICAL PREPARATIONS THAT CONTAIN SUCH 11 BETA-HALOGEN-STRATRIENS REPLACED IN 7 ALPHA, AS WELL AS USED IN THE PREPARATION OF MEDICINES. | |
| UA41875C2 (en) | Method for inhibiting estrogen-dependent tumors using steroid sulfate-containing inhibitors | |
| ES2130390T3 (en) | TAXANES SUBSTITUTED WITH FURYLL OR CARBONYL TENYL AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM. | |
| AR005357A1 (en) | DERIVATIVES OF 14-O-CARBAMOIL MUTILINA AND ITS USEFUL SALTS IN THE TREATMENT OF BACTERIAL INFECTIONS, PROCEDURE FOR PREPARING THEM, PHARMACEUTICAL COMPOSITIONS FORMED WITH SUCH DERIVATIVES AND USE OF THE SAME FOR PREPARING SUCH COMPOSITIONS | |
| MX9205311A (en) | NEW SUBSTITUTED TAXANES AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM | |
| CY1110172T1 (en) | PHARMACEUTICAL COMPOSITIONS OF INCLUSIVE TAHACININ COMPONENTS AND A SEROTONINE REPOSAL INHIBITOR | |
| CO5050310A1 (en) | DISINFECTANT COMPOSITIONS AND PROCESSES TO DISINFECT SURFACES BASES TO DISINFECT SURFACES | |
| RU94031155A (en) | Amidine derivatives, method for their production, their using as inhibitors of no-syntase, pharmaceutical composition, method of treatment | |
| MY106980A (en) | Heterocyclic compounds | |
| ES2102478T3 (en) | VANADIUM COMPLEXES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM. | |
| FI954105A (en) | New 4-aminopyridines, process for their preparation and compounds containing them | |
| PT95266A (en) | PROCESS FOR THE PREPARATION OF QUINONE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
| ES2084129T3 (en) | NEW HETERO CYCLIC CALCONS, ITS PREPARATION PROCEDURE AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM. | |
| ES2307337T3 (en) | ANTI-ANGIOGENIC PEPTIDIC MEDICINES. | |
| ATE234298T1 (en) | CYCLIC ETHER COMPOUNDS AS SODIUM CHANNEL MODULATORS | |
| ATE94061T1 (en) | ARYL-SUBSTITUTED AMINE DERIVATIVES USEFUL IN CANCER THERAPY. | |
| DK0779886T3 (en) | Dihydrobenzofuran and related compounds useful as anti-inflammatory agents | |
| MX9302957A (en) | XANTINA COMPOUNDS, PROCEDURE FOR THE PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. | |
| PT90740A (en) | PROCESS FOR THE PREPARATION OF OLIGOPEPTIDEES WITH CYCLIC PROLINE ANALOGUES, AND OF PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM | |
| DK0879231T3 (en) | Dihydrobenzofuran and related compounds useful as anti-inflammatory agents | |
| AR029618A1 (en) | AMIDA COMPOUNDS, PROCEDURES TO PREPARE THEM, THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THE USE OF SUCH COMPOUNDS FOR THE MANUFACTURE OF MEDICINES | |
| ES2069719T3 (en) | NEW DERIVATIVES OF THIOPHENE, ITS PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM. | |
| DK0891346T3 (en) | Dihydrobenzofuran compounds useful as anti-inflammatory agents | |
| ATE9231T1 (en) | GLASS FIBERS CONTAINING POLYAMIDE COMPOSITIONS AND AN UNSATURATED ACRYLIC COMPOUND. | |
| FI910924A0 (en) | NYA PROPANAMINER, FRAMSTAELLNING AV DESSA OCH ANVAENDNING AV DESSA FOER THERAPEUTIC AENDAMAOL, I SYNNERHET SOM DIARREMEDICINER. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |